## DaxibotulinumtoxinA-lanm (Daxxify®)

Point-of-Sale (POS) edits are safety limitations that are automatically verified through computer programming at the time that a prescription claim is submitted at the pharmacy. These edits can be applied to *any* medication, whether or not it is listed in the Preferred Drug List / Non-Preferred Drug List (PDL/NPDL). The first section of this document is organized to follow the order of the therapeutic classes in the PDL/NPDL and explains the POS edits for those medications.

## **POS Abbreviations**

AL – Age Limit	DS – Maximum Days' Supply Allowed	PU – Prior Use of Other Medication is Required
<b>BH</b> – Behavioral Health Clinical Authorization for Children Younger than 7 Years of Age	<b>DT</b> – Duration of Therapy Limit	<b>QL</b> – Quantity Limit
<b>BY</b> – Diagnosis Codes Bypass Some Requirements	<b>DX</b> – Diagnosis Code Requirement	RX – Specific Prescription Requirement
CL – Additional Clinical Information is Required	<b>ER</b> – Early Refill	<b>TD</b> – Therapeutic Duplication
<b>CU</b> – Concurrent Use with Other Medication is Restricted	MD – Maximum Dose Limit	YQ – Yearly Quantity Limit
<b>DD</b> – Drug-Drug Interaction	MME – Maximum Morphine Milligram Equivalent is Restricted	

## $\textbf{DaxibotulinumtoxinA-lanm} \ (\textbf{Daxxify} \circledast)$

## **POS Edits**

**DX** – Pharmacy claims for this agent must be submitted with an appropriate diagnosis code found at <u>THIS LINK</u>.

Revision / Date	Implementation Date
Created POS Document / August 2024	January 2025